Table 5.
The characteristics of patients with BRCA germline mutations
| Serial Number | Age at diagnosis (yr) | BRCA mutation | Significance | Group assignment | PFS per study (mo) | PFS1 | Recurrence |
| 3 | 50 | BRCA 1, Q1395X (4302C>T) | Deleterious | 1 | 51.2+ | 73.2+ | No |
| 4 | 52 | BRCA 1, 187del AG | Deleterious | 1 | 15.5 | Yes | |
| 7 | 58 | BRCA 1, Q310X | Deleterious | 1 | 14+ | 36+ | No |
| 22 | 56 | BRCA 1, G1706E | Suspected deleterious | 1 | 23.5 | Yes, deceased | |
| 23 | 54 | BRCA 1, unknown | Deleterious | 1 | 12.9 | Yes | |
| 28 | 41 | BRCA 1, C64G (309T>G) | Deleterious | 2 | 35.7+ | 53 | Splenic recurrence, at 53 mo |
| 35 | 40 | BRCA 1, 187delAG | Deleterious | 2 | 29.9+ | 51.9+ | No |
1
Progression free survival (PFS) used the cut of day of 1/30/2019. PFS per study used cut off day of March 30, 2017. PFS: Progression free survival.